Cradle Bio Secures $73M Series B Funding to Revolutionize AI-Driven Protein Engineering

Funding:
Cradle Bio has raised $73 million in Series B funding led by IVP, with continued support from Index Ventures and Kindred Capital, bringing its total funding to over $100 million1 3.

Purpose:
The funding aims to accelerate the adoption of AI-powered protein engineering in labs worldwide, focusing on expanding wet lab capabilities, growing the engineering team, and scaling go-to-market operations1 5.

Impact:
Cradle's platform has shown significant speed-ups in research and development projects (1.2 to 12x) and cost reductions (up to 90%), with a customer satisfaction score of 8+ and adoption by major companies like Novo Nordisk and Johnson & Johnson1.

Expansion:
The funding will help Cradle bring its AI-based protein-making software to more drugmakers and scientific teams, enhancing its presence in pharma and diagnostics2 4.

Goals:
Cradle aims to empower millions of scientists to engineer more sustainable products and better therapeutics, leveraging the versatility of proteins to improve human and planetary health1 3.